| HOME >> BIOLOGY >> TECHNOLOGY |
Amounts, unless specified otherwise, are expressed in U.S. dollars. Financial results are reported under GAAP unless otherwise noted. All per share amounts are stated on a diluted basis unless otherwise noted.
Use of Certain Non GAAP Financial Measures
------------------------------------------
Certain financial results presented in this press release include
non-GAAP measures that exclude certain items. Adjusted net loss from
continuing operations, adjusted net loss per share from continuing
operations and adjusted earnings before interest, taxes, depreciation and
amortization ("Adjusted EBITDA") exclude certain non-cash and non-recurring
items such as acquisition related amortization charges, acquired in-process
research and development relating to license agreements and acquisitions,
stock-based compensation expense, foreign exchange gains or losses relating
to translation of foreign currency cash and investment balances and other
non-recurring items. Adjusted net loss from continuing operations, adjusted
net loss per share from continuing operations and adjusted EBITDA also
exclude litigation expenses related to defending intellectual property
claims. Revenue, as adjusted, excludes non-recurring, non-operating revenue
derived from license agreements and other license revenue, net of license
fees due to licensors and excludes amounts accrued for costs incurred, and
potential future costs, related to our offer to accept returns of Contour
Threads brand product as part of our announced brand name consolidation and
discontinuation. Adjusted net loss from continuing operations, adjusted net
loss per share from continuing operations, revenue, as adjusted, and
adjusted EBITDA do not have any st
'/>"/>
| SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |